Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Heron Therapeutics (HRTX) PT Lowered to $20 at Cantor Fitzgerald
March 1, 2022 7:22 AM ESTCantor Fitzgerald analyst Brandon Folkes lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $20.00 (from $26.00) while maintaining a Neutral rating.
... MoreHeron Therapeutics (HRTX) PT Lowered to $13 at Cowen
March 1, 2022 6:54 AM ESTCowen analyst Boris Peaker lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $13.00 (from $31.00) while maintaining an Outperform rating following disappointing Q4 results.
The analyst commented, "Heron reported disappointing 4Q21 earnings with Zynrelef reaching sales of only $0.8MM (-61% Q/Q). We... More
Heron Therapeutics (HRTX) Tops Q4 EPS by 4c
February 28, 2022 4:28 PM ESTHeron Therapeutics (NASDAQ: HRTX) reported Q4 EPS of ($0.54), $0.04 better than the analyst estimate of ($0.58). Revenue for the quarter came in at $20.66 million versus the consensus estimate of $25.59 million.
For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.
... More